Is telisotuzumab-EMRELIS a targeted drug?

Telisotuzumab (trade name EMRELIS) is a monoclonal antibody drug that belongs to the category of targeted therapy drugs. Its main target is the c-Met receptor tyrosine kinase on the surface of tumor cells. This receptor is highly expressed in a variety of solid tumors and is closely related to tumor cell proliferation, migration and invasion. By specifically binding to c-Met, Telisotuzumab can block its downstream signaling pathways, thereby inhibiting tumor growth and spread.

As a targeted drug, Telisotuzumab has the advantage of strong selectivity and clear mechanism of action. It can act on tumor cells with high expression of c-Met while having less impact on normal tissues. This specificity reduces the widespread toxicities common with traditional chemotherapy drugs, allowing patients to receive better tolerability and quality of life while receiving treatment.

Clinical studies have shown that Telisotuzumab has potential efficacy in non-small cell lung cancer (NSCLC) and other c-Met high-expressing solid tumors. Early clinical trials have shown that single agent or combination therapy can significantly inhibit tumor growth and improve objective response rate (ORR) and progression-free survival (PFS). Therefore, it is not only a new option for anti-tumor treatment, but also embodies the development direction of precision medicine and personalized treatment.

In general, terituzumab (EMRELIS) clearly belongs to the category of targeted drugs. By precisely inhibiting the c-Met signaling pathway, it provides a specialized treatment strategy for patients with tumors with high c-Met expression, while having advantages in safety, tolerability and efficacy. In the future, as more clinical trial data accumulates, Telisotuzumab The application prospects in targeted combination therapy will be broader.

Reference materials:https://www.drugs.com/